A Bachelor of Science graduate from the National University of Singapore, Song has spent almost two decades of his career in the information technology sector.He has held senior management roles in various tech companies, including vice president, Asia Pacific, of Nasdaq-listed Palo Alto Networks, a...

Entrepreneur Peter Koh always focuses on leading by example, because he believes that actions resonate more powerfully than words. “Your title may gain you some form of respect, but people don’t follow your title, they follow courage,” says the CEO of Singapore Exchange (SGX)-listed food techn...

THE following companies saw new developments that may affect trading of their securities on Thursday (Dec 30):

THE following companies saw new developments that may affect trading of their securities on Thursday (Dec 30):

CATALIST-LISTED medtech firm Biolidics announced on Wednesday (Dec 29) that its wholly-owned subsidiary, Biomedics Laboratory, has been granted approval by the Ministry of Health to provide medical microbiology services, including Covid-19 polymerase chain reaction (PCR) tests.

On Dec 8, Biolidics announced it has entered into a definitive agreement with its contract manufacturer for the production of its ClearEpi SARS-CoV-2 Neutralising Antibody Rapid Test Kit (ClearEpi NAB Test) which can be used to detect a person's protective immunity against Covid-19 infections. The c...

CATALIST-LISTED medtech firm Biolidics expects to start commercial production of a new Covid-19 rapid test kit by year-end, the board announced on Wednesday (Dec 8).

BIOLIDICS (8YY) on Monday said it has developed a new ClearEpi NAB Test product which detects an individual's protective immunity against Covid-19.

THE following companies saw new developments that may affect trading of their securities on Tuesday:

SHARES of Catalist-listed medical technology (medtech) players Biolidics and Medtecs International fell on Monday morning, after both companies announced their H1 financial results on Friday following the close of trading.

MEDTECH company Biolidics 8YY posted a S$3 million loss for the six months ended June 2021 - widening from the S$0.1 million loss in the year-ago period - amid a "highly competitive market" with a growing supply of antigen and antibody test kits.

CATALIST-LISTED medtech firm Biolidics on Monday reached an "amicable settlement" with Japan biochip partner Sysmex Corporation "without any admission to liability", putting paid to previous disputes over intellectual property (IP).

Biolidics has received product authorisation from Indonesia’s ministry of health for the usage and distribution of the company’s ClearEpi SARS-CoV-2 Antigen Rapid Test Kit (ClearEpi ART) in Indonesia.  In a filing to SGX dated March 15, the company states that the authorisation remains vali...

MEDTECH firm Biolidics on Monday launched a Covid-19 antigen test kit which can be marketed and sold in the European Union (EU).

In an unrated note published in a question and answer format on Dec 14, PhillipCapital’s research team spoke to Biolidics on the company’s recent developments on its SARS-CoV-2 Antigen Rapid Test Kit and other Covid-19 test kits. In March 2020, the Singapore-based medical technology company laun...